NCT07696247Active, not recruiting
Effect of Agave Inulin Supplementation on Metabolic Profile and Intestinal Abundance of Bifidobacterium and Lactobacillaceae in Adults With Type 2 Diabetes Mellitus
Effects of Eight Weeks of Agave Inulin Supplementation on Metabolic Profile and Intestinal Abundance of Bifidobacterium and Lactobacillaceae in Adults With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of agave inulin supplementation on metabolic profile and intestinal abundance of Bifidobacterium and Lactobacillaceae in adults with type 2 diabetes mellitus. Participants will receive either 10 g/day of agave inulin or a placebo for eight weeks. Clinical, anthropometric, biochemical, and gut microbiota assessments will be performed at baseline and at the end of the intervention. The study seeks to determine whether agave inulin supplementation improves metabolic outcomes and modulates beneficial intestinal microorganisms associated with metabolic health in adults with type 2 diabetes mellitus.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 43 (actual)
- First submitted
- 6 Jul 2026
- Start date
- 1 Apr 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Universidad Autonoma de Queretaro
- Diseases
- Type 2 diabetes
- NCT number
- NCT07696247
What you commit to
- Study type: Interventional
- Participants enrolled: 43
- From 1 Apr 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of probiotics, prebiotics, synbiotics, or fiber supplements within the previous 3 months.
- Use of alpha-glucosidase inhibitors.
Other illness
- Severe cardiovascular disease.
- Chronic kidney disease stage 3b or higher.
- Active gastrointestinal disease.
- Known allergy to agave or fructans.
Lab values
- HbA1c \> 9.5%.
Other
- Pregnancy or lactation.
Who the study is looking for
- Confirmed diagnosis of type 2 diabetes mellitus.
- Age between 20 and 75 years.
- Residence in Querétaro, Mexico.
- Stable oral hypoglycemic treatment and/or basal insulin.
- Ability to provide informed consent.
Age in the registry: 20 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Facultad de Ciencias Naturales, Campus Juriquilla Coordinator of this site? Confirm its status | Querétaro City | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.